TheranoXome · Engineered Exosomes for Stimuli-responsive Image-guided Drug delivery for Cancer Theranostic applications.
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2023-09-01 → 2025-08-31
- Финансиране от ЕС
- 181 153 €
- Участници
- 2
- Схема
- HORIZON-TMA-MSCA-PF-EF
Линиите свързват координатора с партньорите.
Накратко на български
Екзозомите (малки клетъчни мехурчета) се модифицират с наночастици, за да доставят лекарства директно до раковите клетки чрез външен контрол. Това помага за създаването на персонализирана стратегия за лечение, която може да се наблюдава в реално време.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Engineered Exosomes for Stimuli-responsive Image-guided Drug delivery for Cancer Theranostic applications.
The treatment of cancer has been one of the biggest challenges of modern medicine. This stems from the immense complexity of the disease arising due to its heterogenous nature. Different cancers respond to therapeutic treatment of drugs differently due to biological, physical and bio-chemical differences. Recent reports have highlighted that all cells in the body including cancer cells interact with each other through specific modes of communication-specifically through the use of exosomes; which are small lipid compartments in the nanoscale (~100 nm) that bleb off a cell and carry specific information and contain signatures on their surface that allow them to ´home´ to cells of the same type from where they arise. This project tries to utilize and harness this communication module to target cancer cells to deliver therapeutic agents specifically. Additionally, to improve and monitor the use of such exosomes for drug-delivery, it is also envisaged to couple stimuli-responsive and imageable nanoparticles to the exosomes in order to actuate site-specific remote-controlled drug delivery. Thus, the overall objective of this project is to develop a personalized strategy for the treatment of cancer that can be monitored during the treatment process, and can be actuated non-invasively to deliver therapeutic drugs at the target site and time.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The primary objective of this project is to engineer a non-immunogenic cell-membrane mimicking drug delivery vehicle for remote-controlled precision drug delivery. This will be achieved by encapsulating stimuli-responsive & contrast enhancing nanoparticles and drug cargo into endogenous exosomes to develop a therapeutic-cum-diagnostic exosomal system viz; TheranoXome for image-guided stimuli-responsive drug delivery. Such bio-mimetic TheranoXomes if realized will have wide applicability as a universal drug-delivery agent. The project entails three steps: (1) Synthesizing TheranoXomes by template assisted loading of chemotherapeutic drugs, light responsive thermoplasmonic gold nanorods and magnetic nanoparticles as magnetic resonance imaging agents into exosomes; (2) (Bio-)Physicochemical characterization of TheranoXomes including colloidal properties, biomimetics, immuno-compatibility, light-triggered drug release, magnetism (imaging and magnetic guided enrichment) and in vitro studies (2D and 3D cell cultures); (3) Application of TheranoXomes in vivo in a breast tumor bearing mice model. I (the ER) will prepare, characterize and test the materials and application proposed, with the support of a multidisciplinary hub of specialists. The prime training aim of TheranoXome is to provide me with a solid foundation in biomaterials, which will support my future career endeavours, both in the academia or industry, to be an independent researcher, a founder of a start-up company or to become key player in the biomaterials sector. I will be hosted by the Centre for Research in Biological Chemistry and Molecular Materials (CiQUS) of the University of Santiago de Compostela, a cutting-edge multidisciplinary research centre at the interface of chemistry, biomedicine and molecular materials. The training will be further strengthened by one secondment (6 months) focused on in vivo (drug delivery and imaging) studies (Health Research Institute of Santiago de Compostela - IDIS).
Оригинален текст от CORDIS (на английски).
Участници
Връзки
- Виж в CORDIS
- DOI: 10.3030/101064817
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e50a8e57ff&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5206694a7&appId=PPGMS
Данни: CORDIS, © Европейски съюз